Global Hepatitis A and B Vaccine market growth is projected to reach  US$ 1849 million in 2025 to US$ 2066 million in 2031; it is expected to grow at a CAGR of 1.9% from 2025 to 2031.

Global Hepatitis A and B Vaccine Market Trends and Analysis 2025-31

The global Hepatitis A and B Vaccine market size is predicted to grow from US$ 1849 million in 2025 to US$ 2066 million in 2031; it is expected to grow at a CAGR of 1.9% from 2025 to 2031. The hepatitis A and hepatitis B vaccinescan be given separately or as a combination vaccine. All the shots in the series are needed for long-term protection. The full series of the hepatitis A and hepatitis B vaccines require 2-3 shots, depending on the type of vaccine. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. Infinity Market Research newest research report, the Hepatitis A and B Vaccine Industry Forecast looks at past sales and reviews total world Hepatitis A and B Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Hepatitis A and B Vaccine sales for 2025 through 2031. With Hepatitis A and B Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hepatitis A and B Vaccine industry. This Insight Report provides a comprehensive analysis of the global Hepatitis A and B Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hepatitis A and B Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Hepatitis A and B Vaccine market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hepatitis A and B Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hepatitis A and B Vaccine. This report presents a comprehensive overview, market shares, and growth opportunities of Hepatitis A and B Vaccine market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Hepatitis A Vaccination &nbsp;&nbsp;&nbsp; Hepatitis B Vaccination Segmentation by Application: &nbsp;&nbsp;&nbsp; Government Institution &nbsp;&nbsp;&nbsp; Private Sector &nbsp;&nbsp;&nbsp; Other This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; GSK &nbsp;&nbsp;&nbsp; Merck &nbsp;&nbsp;&nbsp; Sanofi &nbsp;&nbsp;&nbsp; Sinovac &nbsp;&nbsp;&nbsp; Zhejiang Pukang &nbsp;&nbsp;&nbsp; Changchun Institute of Biological &nbsp;&nbsp;&nbsp; KM Biologics &nbsp;&nbsp;&nbsp; IMBCAMS &nbsp;&nbsp;&nbsp; Convac &nbsp;&nbsp;&nbsp; NCPC &nbsp;&nbsp;&nbsp; Bio Kangtai &nbsp;&nbsp;&nbsp; Dynavax &nbsp;&nbsp;&nbsp; Hissen &nbsp;&nbsp;&nbsp; LG Life Sciences &nbsp;&nbsp;&nbsp; Serum Institute Key Questions Addressed in this Report What is the 10-year outlook for the global Hepatitis A and B Vaccine market? What factors are driving Hepatitis A and B Vaccine market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Hepatitis A and B Vaccine market opportunities vary by end market size? How does Hepatitis A and B Vaccine break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Hepatitis A and B Vaccine Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Hepatitis A and B Vaccine by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Hepatitis A and B Vaccine by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Hepatitis A and B Vaccine Segment by Type &nbsp;2.2.1 Hepatitis A Vaccination &nbsp;2.2.2 Hepatitis B Vaccination &nbsp;2.3 Hepatitis A and B Vaccine Sales by Type &nbsp;2.3.1 Global Hepatitis A and B Vaccine Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Hepatitis A and B Vaccine Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Hepatitis A and B Vaccine Sale Price by Type (2020-2025) &nbsp;2.4 Hepatitis A and B Vaccine Segment by Application &nbsp;2.4.1 Government Institution &nbsp;2.4.2 Private Sector &nbsp;2.4.3 Other &nbsp;2.5 Hepatitis A and B Vaccine Sales by Application &nbsp;2.5.1 Global Hepatitis A and B Vaccine Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Hepatitis A and B Vaccine Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Hepatitis A and B Vaccine Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Hepatitis A and B Vaccine Breakdown Data by Company &nbsp;3.1.1 Global Hepatitis A and B Vaccine Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Hepatitis A and B Vaccine Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Hepatitis A and B Vaccine Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Hepatitis A and B Vaccine Revenue by Company (2020-2025) &nbsp;3.2.2 Global Hepatitis A and B Vaccine Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Hepatitis A and B Vaccine Sale Price by Company &nbsp;3.4 Key Manufacturers Hepatitis A and B Vaccine Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Hepatitis A and B Vaccine Product Location Distribution &nbsp;3.4.2 Players Hepatitis A and B Vaccine Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Hepatitis A and B Vaccine by Geographic Region &nbsp;4.1 World Historic Hepatitis A and B Vaccine Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Hepatitis A and B Vaccine Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Hepatitis A and B Vaccine Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Hepatitis A and B Vaccine Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Hepatitis A and B Vaccine Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Hepatitis A and B Vaccine Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Hepatitis A and B Vaccine Sales Growth &nbsp;4.4 APAC Hepatitis A and B Vaccine Sales Growth &nbsp;4.5 Europe Hepatitis A and B Vaccine Sales Growth &nbsp;4.6 Middle East & Africa Hepatitis A and B Vaccine Sales Growth 5 Americas &nbsp;5.1 Americas Hepatitis A and B Vaccine Sales by Country &nbsp;5.1.1 Americas Hepatitis A and B Vaccine Sales by Country (2020-2025) &nbsp;5.1.2 Americas Hepatitis A and B Vaccine Revenue by Country (2020-2025) &nbsp;5.2 Americas Hepatitis A and B Vaccine Sales by Type (2020-2025) &nbsp;5.3 Americas Hepatitis A and B Vaccine Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Hepatitis A and B Vaccine Sales by Region &nbsp;6.1.1 APAC Hepatitis A and B Vaccine Sales by Region (2020-2025) &nbsp;6.1.2 APAC Hepatitis A and B Vaccine Revenue by Region (2020-2025) &nbsp;6.2 APAC Hepatitis A and B Vaccine Sales by Type (2020-2025) &nbsp;6.3 APAC Hepatitis A and B Vaccine Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Hepatitis A and B Vaccine by Country &nbsp;7.1.1 Europe Hepatitis A and B Vaccine Sales by Country (2020-2025) &nbsp;7.1.2 Europe Hepatitis A and B Vaccine Revenue by Country (2020-2025) &nbsp;7.2 Europe Hepatitis A and B Vaccine Sales by Type (2020-2025) &nbsp;7.3 Europe Hepatitis A and B Vaccine Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Hepatitis A and B Vaccine by Country &nbsp;8.1.1 Middle East & Africa Hepatitis A and B Vaccine Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Hepatitis A and B Vaccine Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Hepatitis A and B Vaccine Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Hepatitis A and B Vaccine Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Hepatitis A and B Vaccine &nbsp;10.3 Manufacturing Process Analysis of Hepatitis A and B Vaccine &nbsp;10.4 Industry Chain Structure of Hepatitis A and B Vaccine 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Hepatitis A and B Vaccine Distributors &nbsp;11.3 Hepatitis A and B Vaccine Customer 12 World Forecast Review for Hepatitis A and B Vaccine by Geographic Region &nbsp;12.1 Global Hepatitis A and B Vaccine Market Size Forecast by Region &nbsp;12.1.1 Global Hepatitis A and B Vaccine Forecast by Region (2026-2031) &nbsp;12.1.2 Global Hepatitis A and B Vaccine Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Hepatitis A and B Vaccine Forecast by Type (2026-2031) &nbsp;12.7 Global Hepatitis A and B Vaccine Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 GSK &nbsp;13.1.1 GSK Company Information &nbsp;13.1.2 GSK Hepatitis A and B Vaccine Product Portfolios and Specifications &nbsp;13.1.3 GSK Hepatitis A and B Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 GSK Main Business Overview &nbsp;13.1.5 GSK Latest Developments &nbsp;13.2 Merck &nbsp;13.2.1 Merck Company Information &nbsp;13.2.2 Merck Hepatitis A and B Vaccine Product Portfolios and Specifications &nbsp;13.2.3 Merck Hepatitis A and B Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 Merck Main Business Overview &nbsp;13.2.5 Merck Latest Developments &nbsp;13.3 Sanofi &nbsp;13.3.1 Sanofi Company Information &nbsp;13.3.2 Sanofi Hepatitis A and B Vaccine Product Portfolios and Specifications &nbsp;13.3.3 Sanofi Hepatitis A and B Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Sanofi Main Business Overview &nbsp;13.3.5 Sanofi Latest Developments &nbsp;13.4 Sinovac &nbsp;13.4.1 Sinovac Company Information &nbsp;13.4.2 Sinovac Hepatitis A and B Vaccine Product Portfolios and Specifications &nbsp;13.4.3 Sinovac Hepatitis A and B Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 Sinovac Main Business Overview &nbsp;13.4.5 Sinovac Latest Developments &nbsp;13.5 Zhejiang Pukang &nbsp;13.5.1 Zhejiang Pukang Company Information &nbsp;13.5.2 Zhejiang Pukang Hepatitis A and B Vaccine Product Portfolios and Specifications &nbsp;13.5.3 Zhejiang Pukang Hepatitis A and B Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 Zhejiang Pukang Main Business Overview &nbsp;13.5.5 Zhejiang Pukang Latest Developments &nbsp;13.6 Changchun Institute of Biological &nbsp;13.6.1 Changchun Institute of Biological Company Information &nbsp;13.6.2 Changchun Institute of Biological Hepatitis A and B Vaccine Product Portfolios and Specifications &nbsp;13.6.3 Changchun Institute of Biological Hepatitis A and B Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 Changchun Institute of Biological Main Business Overview &nbsp;13.6.5 Changchun Institute of Biological Latest Developments &nbsp;13.7 KM Biologics &nbsp;13.7.1 KM Biologics Company Information &nbsp;13.7.2 KM Biologics Hepatitis A and B Vaccine Product Portfolios and Specifications &nbsp;13.7.3 KM Biologics Hepatitis A and B Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 KM Biologics Main Business Overview &nbsp;13.7.5 KM Biologics Latest Developments &nbsp;13.8 IMBCAMS &nbsp;13.8.1 IMBCAMS Company Information &nbsp;13.8.2 IMBCAMS Hepatitis A and B Vaccine Product Portfolios and Specifications &nbsp;13.8.3 IMBCAMS Hepatitis A and B Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.8.4 IMBCAMS Main Business Overview &nbsp;13.8.5 IMBCAMS Latest Developments &nbsp;13.9 Convac &nbsp;13.9.1 Convac Company Information &nbsp;13.9.2 Convac Hepatitis A and B Vaccine Product Portfolios and Specifications &nbsp;13.9.3 Convac Hepatitis A and B Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.9.4 Convac Main Business Overview &nbsp;13.9.5 Convac Latest Developments &nbsp;13.10 NCPC &nbsp;13.10.1 NCPC Company Information &nbsp;13.10.2 NCPC Hepatitis A and B Vaccine Product Portfolios and Specifications &nbsp;13.10.3 NCPC Hepatitis A and B Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.10.4 NCPC Main Business Overview &nbsp;13.10.5 NCPC Latest Developments &nbsp;13.11 Bio Kangtai &nbsp;13.11.1 Bio Kangtai Company Information &nbsp;13.11.2 Bio Kangtai Hepatitis A and B Vaccine Product Portfolios and Specifications &nbsp;13.11.3 Bio Kangtai Hepatitis A and B Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.11.4 Bio Kangtai Main Business Overview &nbsp;13.11.5 Bio Kangtai Latest Developments &nbsp;13.12 Dynavax &nbsp;13.12.1 Dynavax Company Information &nbsp;13.12.2 Dynavax Hepatitis A and B Vaccine Product Portfolios and Specifications &nbsp;13.12.3 Dynavax Hepatitis A and B Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.12.4 Dynavax Main Business Overview &nbsp;13.12.5 Dynavax Latest Developments &nbsp;13.13 Hissen &nbsp;13.13.1 Hissen Company Information &nbsp;13.13.2 Hissen Hepatitis A and B Vaccine Product Portfolios and Specifications &nbsp;13.13.3 Hissen Hepatitis A and B Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.13.4 Hissen Main Business Overview &nbsp;13.13.5 Hissen Latest Developments &nbsp;13.14 LG Life Sciences &nbsp;13.14.1 LG Life Sciences Company Information &nbsp;13.14.2 LG Life Sciences Hepatitis A and B Vaccine Product Portfolios and Specifications &nbsp;13.14.3 LG Life Sciences Hepatitis A and B Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.14.4 LG Life Sciences Main Business Overview &nbsp;13.14.5 LG Life Sciences Latest Developments &nbsp;13.15 Serum Institute &nbsp;13.15.1 Serum Institute Company Information &nbsp;13.15.2 Serum Institute Hepatitis A and B Vaccine Product Portfolios and Specifications &nbsp;13.15.3 Serum Institute Hepatitis A and B Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.15.4 Serum Institute Main Business Overview &nbsp;13.15.5 Serum Institute Latest Developments 14 Research Findings and Conclusion

Report	Global Hepatitis A and B Vaccine Market Growth 2025-2031
Selected License	Single ID:LPI13677

Buyer Information

Order Summary